18F-DCFPyL PET/CT在前列腺癌亚临床复发患者中的应用:病灶大小、平滑滤波与部分容积校正对PROMISE标准的影响
研究纳入75例生化复发且CT和骨显像阴性的前列腺癌男性患者,共232个直径小于12 mm的转移淋巴结,评估平滑滤波与部分容积校正(PVC)对PSMA活性测量及miPSMA评分的影响。校正后平均SUVmax由11.0±9.3升至28.5±22.8(P<0.00001),并推导出按病灶大小分层的简易经验校正因子;校正数据集与经验法则数据集的miPSMA评分在205/232个病灶(88.4%)中一致。
要点
- 平滑滤波与PVC使小淋巴结转移灶的PSMA活性测量值明显升高,并影响miPSMA评分。
- 按病灶大小推导的经验校正因子:<4 mm为4,4-7 mm为2.8,7-9 mm为2.3,9-12 mm为1.8。
- 经验法则校正后的miPSMA评分与实测校正数据集在88.4%(205/232)的病灶中一致。
核心结论
- 平滑滤波与PVC对小的淋巴结转移灶所测PSMA活性有显著影响,并影响miPSMA评分。
研究设计与样本
- 研究纳入75例前列腺癌生化复发且CT和骨显像阴性的男性,转诊行18F-DCFPyL PET/CT,检查在两种不同品牌的PET/CT扫描仪之一上完成。
- 所有可疑肿瘤部位在配准的CT和PET图像上手动勾画,并按PROMISE标准赋予miPSMA评分;利用解剖CT为每个病灶计算PVC因子并应用于未平滑的PET图像。
- 比较校正与未校正的miPSMA评分,并为不同大小病灶(<4 mm、4-7 mm、7-9 mm、9-12 mm)推导简化的经验法则校正因子,再应用于原始数据集并与实际校正所得miPSMA评分比较。
主要发现
- 共75例男性(中位年龄69岁;中位血清PSA 3.69 μg/L),232个直径小于12 mm的转移淋巴结(平均病灶体积313.5±309.6 mm3)。
- 校正前平均SUVmax为11.0±9.3,校正后为28.5±22.8(P<0.00001)。
- 病灶小于4 mm(n=22)、4-7 mm(n=140)、7-9 mm(n=50)、9-12 mm(n=20)的平均校正因子分别为4(范围2.5-6.4)、2.8(范围1.6-4.9)、2.3(范围1.6-3.3)、1.8(范围1.4-2.4)。
- 校正数据集与经验法则数据集的miPSMA评分总体在232个病灶中的205个(88.4%)一致。
关键数值与推荐
- miPSMA评分按PROMISE标准赋予。
- 校正前平均SUVmax 11.0±9.3 vs 校正后28.5±22.8(P<0.00001)。
- 病灶小于4 mm(n=22)平均校正因子4(范围2.5-6.4)。
- 病灶4-7 mm(n=140)平均校正因子2.8(范围1.6-4.9)。
- 病灶7-9 mm(n=50)平均校正因子2.3(范围1.6-3.3);病灶9-12 mm(n=20)平均校正因子1.8(范围1.4-2.4)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Our purpose was to determine the effect of a smoothing filter and partial-volume correction (PVC) on measured prostate-specific membrane antigen (PSMA) activity in small metastatic lesions and to determine the impact of these changes on molecular imaging PSMA (miPSMA) scoring. Methods: Men who had biochemical recurrence of prostate cancer with negative findings on CT and bone scintigraphy were referred for 18F-DCFPyL (2-(3-(1-carboxy-5-[(6-18F-fluoro-pyridine-3-carbonyl)-amino]-pentyl) PET/CT. Examinations were performed on 1 of 2 different brands of PET/CT scanner. All suspected tumor sites were manually contoured on coregistered CT and PET images, and each was assigned an miPSMA score as per the PROMISE criteria. The PVC factors were calculated for every lesion using the anatomic CT and then applied to the unsmoothed PET images. The miPSMA scores, with and without the corrections, were compared, and a simplified rule-of-thumb (RoT) correction factor (CF) was derived for lesions at various sizes (<4 mm, 4-7 mm, 7-9 mm, and 9-12 mm). This CF was then applied to the original dataset and the miPSMA scores that were obtained using the RoT CF were compared with those obtained using the actual corrections. Results: There were 75 men (median age, 69 y; median serum PSA, 3.69 μg/L) with 232 metastatic nodes less than 12 mm in diameter (mean lesion volume, 313.5 ± 309.6 mm3). The mean SUVmax before and after correction was 11.0 ± 9.3 and 28.5 ± 22.8, respectively (P < 0.00001). The mean CF for lesions smaller than 4 mm (n = 22), 4-7 mm (n = 140), 7-9 mm (n = 50), and 9-12 mm (n = 20) was 4 (range, 2.5-6.4), 2.8 (range, 1.6-4.9), 2.3 (range, 1.6-3.3), and 1.8 (range, 1.4-2.4), respectively. Overall, the miPSMA scores were concordant between the corrected dataset and the RoT dataset for 205 of 232 lesions (88.4%). Conclusion: A smoothing filter and PVC had a significant effect on measured PSMA activity in small nodal metastases, impacting the miPSMA score.
引用
- Ortega C, Schaefferkoetter J, Veit-Haibach P, et al. 18F-DCFPyL PET/CT in Patients with Subclinical Recurrence of Prostate Cancer: Effect of Lesion Size, Smoothing Filter, and Partial-Volume Correction on PROMISE Criteria. J Nucl Med. 2020. PMID: 32198311. doi:10.2967/jnumed.120.241737
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。